Management of Cervical Intraepithelial Neoplasia Grade 2
Launched by UNIVERSIDADE CIDADE DE SAO PAULO · Aug 11, 2008
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
Pap smear and colposcopy were performed at every follow-up visit and all lesions were completely visible at colposcopy.
The researchers purpose was to make some comments about the over treatment and the misclassification of CIN 2.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Histological CIN2 diagnosis
- Exclusion Criteria:
- • Previous CIN treatment
About Universidade Cidade De Sao Paulo
Universidade Cidade de São Paulo (UCSP) is a distinguished academic institution dedicated to advancing medical research and clinical trials. With a commitment to innovation and excellence, UCSP leverages its multidisciplinary expertise to facilitate groundbreaking studies that address critical health challenges. The university fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements. Through its rigorous research initiatives, UCSP aims to contribute valuable insights to the medical community and improve patient outcomes on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
São Paulo, , Brazil
Patients applied
Trial Officials
Sylvia F Brenna, MD, PhD
Principal Investigator
Universidade Cidade de Sao Paulo
Ana C Guedes, MD, PhD
Principal Investigator
Universidade Cidade de Sao Paulo
Kari J Sirjanen, MD, PhD
Study Chair
University of Turku
Luis C Zeferino, MD, PhD
Study Director
University of Campinas, Brazil
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials